Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

July 31, 2013

Study Completion Date

April 30, 2015

Conditions
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Interventions
DRUG

Bendamustine

90 mg/m2/day IV days 1 and 2 every 28 days for 6 cycles

DRUG

Rituximab

375 mg/m2 Day 1 every 28 days for 6 cycles

DRUG

Lenalidomide

5 mg/day days 1-28 of each 28 day cycle, up to 12 cycles maximum. Dose escalation to 10 mg/day allowed after one cycle as defined in the protocol.

Trial Locations (10)

53066

Oconomowoc Memorial Hospital, Oconomowoc

53188

Waukesha Memorial Hospital, Waukesha

53226

Medical College of Wisconsin, Milwaukee

53548

Mercy Health System Heme/Onc, Janesville

53792

University of Wisconsin Carbone Cancer Center, Madison

54301

St Vincent Regional Cancer Center, Green Bay

54313

Bellin Memorial Hospital, Green Bay

54449

Marshfield Clinic, Marshfield

54494

Riverview Hospital, Wisconsin Rapids

54601

Gundersen Clinic, La Crosse

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

University of Wisconsin, Madison

OTHER